Gliclazide enhances exercise performance and recovery of muscle strength in healthy trained individuals: a randomized controlled trial

Author:

Martins Jocelito Bijoldo1,Dipp Thiago1,Schaan Beatriz D.2,Lehnen Alexandre Machado1

Affiliation:

1. Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia

2. Hospital de Clínicas de Porto Alegre

Abstract

Abstract

To examine the acute effect of gliclazide on exercise performance and recovery of muscle strength in healthy participants. We conducted a randomized, double-blind, placebo-controlled crossover clinical trial in 44 strength-trained men. They were allocated to gliclazide modified release (MR) (90mg, 8h before exercise sessions) or placebo, undergo three consecutive sessions of strength exercise (four sets, 80% of one-repetition maximum [1-RM] of bench press and free squat exercise). We evaluated total volume-load (VL) (#repetitions x 80%1-RM), range of motion (ROM), insulin and glucose levels, creatine kinase MM (CK-MM), lactate dehydrogenase (LDH), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), hemodynamic parameters, perceived pain and recovery scores. Gliclazide enhanced strength exercise performance with improvements in total VL (bench press 23.3%, p < 0.001; squats 23.2%, p < 0.001), and improved muscle recovery 24-48h post-exercise: ROM (shoulder 1.1%, p < 0.001; knee 1.6%, p = 0.004), CK-MM (–13.2%, p < 0.001), LDH (–12.8%, p < 0.001), TNF-α (–17.4%, p < 0.001), IL-6 (–5.3%, p < 0.001), pain (–17.7%, p < 0.001) and recovery scores (32.5%, p = 0.001). However, hypoglycemia events were observed in 3 participants in the gliclazide group. In conclusion, Gliclazide MR 90mg, 8h before strength exercise, produced ergogenic effects (exercise performance and muscle recovery), although hypoglycemia was observed in 7% of subjects. Registration: “www.clinicaltrials.gov”, “NCT04443777” (Primary Completion: 01/08/2020; Study Completion: 31/10/2023).

Publisher

Springer Science and Business Media LLC

Reference49 articles.

1. Pharmacological Management of Diabetes Mellitus: A Century of Expert Opinions in Cecil Textbook of Medicine;Manu P;Am J Ther,2021

2. Keitel, S. Pharmacopoeial Standards: European Pharmacopoeia. in Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition 2691–2703 (CRC Press, 2013).

3. Draznin, B., et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 45, S125-s143 (2022).

4. Sulfonylurea stimulation of insulin secretion;Proks P;Diabetes,2002

5. Agency, W.A.D. Prohibited list 2023.. (Canada, 2023).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3